Anavex Life Sciences Corp.
13
0
1
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of ANAVEX3-71 in Adults With Schizophrenia
Role: lead
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Role: lead
ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome
Role: lead
Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
Role: collaborator
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Role: lead
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Role: lead
ANAVEX2-73 Study in Patients With Rett Syndrome
Role: lead
Phase 1 Study of ANAVEX3-71
Role: lead
Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects
Role: collaborator
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Role: lead
Study of ANAVEX2-73 in Patients With Rett Syndrome
Role: lead
ANAVEX2-73 Study in Parkinson's Disease Dementia
Role: lead
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
Role: lead
All 13 trials loaded